Navigation Links
Studies Struggle to Gauge Glucosamine's Worth
Date:2/1/2009

But many doctors insist the supplement is safe and worth a try for arthritis pain

FRIDAY, Jan. 30 (HealthDay News) -- Eager to relieve joint pain and repair the cushioning between bones, millions of arthritis sufferers reach for glucosamine, an over-the-counter dietary supplement.

Despite its popularity, studies examining the effectiveness of this natural therapy have yielded mixed results.

"There is still a lot of uncertainty about glucosamine," said Dr. Steven C. Vlad, a fellow in clinical epidemiology and rheumatology at Boston University School of Medicine.

So what is glucosamine, anyway? It's a type of sugar that the body produces and distributes in cartilage and other connective tissue. Chondroitin sulfate, often taken in combination with glucosamine, is a complex carbohydrate that helps cartilage retain water, according to the U.S. National Center for Complementary and Alternative Medicine.

These substances are derived from animal tissues, according to the Arthritis Foundation. Glucosamine is extracted from crab, lobster or shrimp shells, and chondroitin sulfate comes from animal cartilage, such as tracheas or shark cartilage.

Vlad's own study tried to determine why the results of glucosamine trials differed so widely. Of the 15 studies he reviewed, there was one clear finding: A particular glucosamine preparation, called glucosamine hydrochloride, doesn't work.

Results among trials involving another common preparation, glucosamine sulfate, showed wide variation -- more than would be expected by chance. Based on the evidence, Vlad concluded that supplement industry support could be a source of bias in some of these studies.

Although critics questioned Vlad's finding, he stands by the results. "Numerous analyses have showed that industry funding is correlated with stronger findings and selective publication of positive results," he noted.

More recently, researchers at the University of Utah School of Medicine reported results from a follow-up to an earlier glucosamine trial. Arthritis patients in this leg of the study took glucosamine; a combination of glucosamine and chondroitin; the anti-inflammatory drug celecoxib (Celebrex), or a placebo. X-rays were taken of patients' knees before the trial began and one and two years later to determine whether glucosamine alone, or in combination with chondroitin, would slow the loss of cartilage.

Lead author Dr. Allen D. Sawitzke, an associate professor of internal medicine at the University of Utah School of Medicine, said he and his colleagues had hoped to have enough patients and measurement accuracy to be able to show some slowing of the damage, but in the end, the results were inconclusive.

"So, it's an example of a null study, that is, a study where there is no difference detected, which isn't the same as saying there is no difference," Sawitzke said.

Dr. Jason Theodosakis, an assistant professor at the University of Arizona College of Medicine and author of the book, The Arthritis Cure, said the study was flawed in many ways, including the small sample size, short duration and imprecise X-ray methodology. "I really can't believe it was even published," he said.

Like many physicians, Theodosakis continues to recommend glucosamine and chondroitin. "This study does nothing to discourage that," he said.

Trying glucosamine for 60 days makes sense, especially for patients who can't tolerate ibuprofen or other nonsteroidal anti-inflammatory drugs, said Dr. Stephen Dahmer, a former fellow in integrative medicine at Beth Israel Medical Center in New York City, and now a staff physician at the VA San Diego Medical Center.

Sawitzke said he sees some merit in the supplement for pain relief, but there's a lot less evidence to support glucosamine as a way to slow cartilage damage.

Vlad, however, tells patients he's doubtful it works very well, if at all. "But I also tell them that it is safe and will not hurt them. If they want to try it, they are more than free to do so at any time, with the understanding that no insurance company will pay for it."

More information

For advice on choosing a pain medicine, visit the U.S. Department of Health and Human Services.



SOURCES: Steven C. Vlad, M.D., fellow, clinical epidemiology and rheumatology, Boston University School of Medicine; Allen D. Sawitzke, M.D., associate professor, medicine, University of Utah School of Medicine, Salt Lake City; Jason Theodosakis, M.D., assistant professor, University of Arizona College of Medicine, and author, The Arthritis Cure; Stephen Dahmer, M.D., staff physician, VA San Diego Medical Center; U.S. National Center for Complementary and Alternative Medicine, Bethesda, Md.; Arthritis Foundation, Atlanta; July 2007 and October 2008 Arthritis & Rheumatism; Aug. 15, 2008, American Family Physician


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Skin color studies on tadpoles lead to cancer advance
2. Nuvo Research Announces Successful Completion Of All Pennsaid(R) Studies
3. Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
4. American Heart Association 2008 Wrap-Up Report: Top Research Advances Include Studies That Influence Medical Care, Apply Science To Real World Communities
5. Zebrafish Journal Publishes Skin Pigmentation Studies That Shed Light on the Evolution of Race
6. Diabetes and Cardiovascular Disease: Online Presentation Looks at the Complex Relationship of These Two Diseases in Light of Recent Studies
7. Studies Challenge Framingham Risk Score
8. Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
9. Eating More Fish a Wise New Year Resolution, Studies Show
10. Studies on Smoking Genes and Transcriptional Control of Chronic Fatigue Syndrome Revealed in Molecular Medicine
11. Rockefeller Universitys Center for Clinical and Translational Science funds 18 new pilot studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... , ... April 25, 2017 , ... ... they rely on contracted partners to help with process innovation in drug formulation ... drug formulation experience along with state-of-the-art analytical equipment in support of their development ...
(Date:4/25/2017)... ... , ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace – ... but be heartened by the industry’s current surge. But another thing that unifies them ... At last they can simply, safely and effectively end their aroma anguish thanks ...
(Date:4/25/2017)... ... 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley ... in Writing, set to publish in summer 2017. , Dr. Bobrow, MD, FACEP, ... Arizona College of Medicine. He also serves as Medical Director for the Bureau of ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... solutions, announces the continuation of its strategic partnership with and platinum sponsorship of ... nations in the safe and effective management of complex spine deformity cases, particularly ...
(Date:4/24/2017)... ... , ... Michael Vick announced his retirement earlier this year from the NFL ... one pick in the 2001 NFL Draft, to the Atlanta Falcons, made four Pro ... career rushing yards by a quarterback (6,109) and the most rushing yards by a ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... PARIS , April 20, 2017 ... EyeCET platform, the first non-viral gene expression technology that ... in the eye to address a wide range of ... UK Medicines and Healthcare products Regulatory Agency (MHRA) to ... ...
(Date:4/19/2017)... -- Cardiology devices segment is anticipated to reach the highest ... Devices segment is likely to create absolute $ opportunity of ... 2017. By the end of 2027, Cardiology Devices segment is ... Mn, expanding at a CAGR of 18.4% over the forecast ... Pacific reprocessed medical devices market in terms of ...
(Date:4/19/2017)... 2017 Global Prostate Cancer Therapeutics Market: ... prostate cancer therapeutics market analyzes the current and ... of prostate cancer, launch of promising emerging therapies, ... new drugs & therapeutic biological products, and high ... lesser side effects are some of the drivers ...
Breaking Medicine Technology: